Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Mosonmagyaróvár – page 37

479 clinical trials in Mosonmagyaróvár, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mosonmagyaróvár at a glance
479
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

479 trials in Mosonmagyaróvár

Open in trial search

Deep vein thrombosis+1

Not recruiting

Study on the Effectiveness and Safety of BAY 3018250 and Low Molecular Weight Heparin for Patients with Proximal Deep Vein Thrombosis

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:BAY 3018250
  • Sponsor:Bayer AG

Long-Term Study on Aflibercept for Retinopathy of Prematurity in Infants

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Aflibercept
  • Sponsor:Bayer AG

Study of XPro1595 for Patients with Early Alzheimer's Disease and Inflammation Markers

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pegipanermin
  • Sponsor:Inmune Bio Inc.

Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Stage III Non-Small Cell Lung Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Hodgkin's disease

Not recruiting

Study of Pembrolizumab with Chemotherapy for Children and Young Adults with Classical Hodgkin Lymphoma Not Responding Well to Initial Treatment

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Bleomycin
  • Sponsor:Merck Sharp & Dohme LLC

Myelofibrosis

Not recruiting

Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Newly Diagnosed Limited-Stage Small Cell Lung Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Multiple sclerosis+2

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab, Methylprednisolone, and Diphenhydramine Hydrochloride in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Effectiveness and Safety of CAM2029 Compared to Octreotide and Lanreotide in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Camurus AB

Erosive oesophagitis

Not recruiting

Study on the Effects and Safety of Pantoprazole for Children and Teens with Healed Erosive Esophagitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Pantoprazole Sodium Sesquihydrate
  • Sponsor:Pfizer Inc.

Study of Pembrolizumab with Drug Combination for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Boserolimab
  • Sponsor:Merck Sharp & Dohme LLC

Bladder cancer+2

Not recruiting

Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Mosonmagyaróvár

What the registry says about research in the country

01 Respiratory Medicine

Multiple innovative trials focusing on moderate to severe asthma management, testing new therapeutic approaches including lunsekimig, dupilumab, and amlitelimab. Research aims to prevent lung function decline and reduce exacerbations.

  • Asthma Exacerbation Prevention
  • Lung Function Preservation
  • Novel Treatment Evaluation

Studies particularly emphasize long-term safety and efficacy in patients with eosinophilic phenotype.

02 Pulmonary Disease Management

Clinical research focusing on Chronic Obstructive Pulmonary Disease (COPD), evaluating new treatments like itepekimab and investigating improved delivery systems for existing medications.

  • COPD Exacerbation Reduction
  • Long-term Treatment Safety
  • Inhaler Technology Innovation

Emphasis on moderate to severe COPD patients and former smokers.

03 Cardiovascular Research

Comprehensive studies in heart failure and atrial fibrillation, testing breakthrough treatments including ponsegromab, milvexian, and vericiguat for improved patient outcomes.

  • Stroke Prevention
  • Heart Failure Management
  • Cardiovascular Event Prevention

Focus on reducing major adverse cardiovascular events and improving quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.